Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
| ▸ | F2R | P25116 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | CA9 | Q16790 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2847700 | 1.00 | HPGD (0.40) | HPGDITGB3ITGA2BF2RALDH1A1 | |
| SCHEMBL971781 | 1.00 | HPGD (0.40) | HPGDITGB3ITGA2BF2RALDH1A1 | |
| SCHEMBL969838 | 0.90 | SMN1; SMN2 (0.38) | HPGDALDH1A1SMN1; SMN2GAANPC1 | |
| SCHEMBL895391 | 0.90 | SMN1; SMN2 (0.38) | HPGDALDH1A1SMN1; SMN2GAANPC1 | |
| SCHEMBL586633 | 0.90 | SMN1; SMN2 (0.38) | HPGDALDH1A1SMN1; SMN2GAANPC1 | |
| SCHEMBL15321741 | 0.83 | BCHE (0.50) | HPGDITGB3ITGA2BF2RALDH1A1 | |
| SCHEMBL3713407 | 0.83 | — | — | |
| SCHEMBL442932 | 0.81 | MEN1 (0.56) | HPGDALDH1A1 | |
| SCHEMBL1249710 | 0.81 | MEN1 (0.56) | HPGDALDH1A1 | |
| SCHEMBL968401 | 0.81 | MEN1 (0.56) | HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024149728-A1 | SUBSTITUTED (HETERO)ANILINES AND THEIR USE | ASTRAZENECA AB (SE) | 2024-07-18 | — | — | WO | disclosed |
| US-9187469-B2 | Morpholinylbenzotriazines for use in cancer therapy | MERCK PATENT GMBH (DE) | 2015-11-17 | — | — | US | disclosed |
| EP-2283000-B1 | 3- OR 4-SUBSTITUTED PIPERIDINE COMPOUNDS | SK BIOPHARMACEUTICALS CO LTD (KR) | 2015-09-23 | — | — | EP | disclosed |
| US-20140275072-A1 | MORPHOLINYLBENZOTRIAZINES FOR USE IN CANCER THERAPY | MERCK PATENT GMBH (DE) | 2014-09-18 | — | — | US | disclosed |
| US-8546576-B2 | 3 or 4-substituted piperidine compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2013-10-01 | — | — | US | disclosed |
| US-8513285-B2 | 3 or 4-substituted piperidine compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2013-08-20 | — | — | US | disclosed |
| US-20120122927-A1 | 3 OR 4-SUBSTITUTED PIPERIDINE COMPOUNDS | LEE KI-HO (KR) | 2012-05-17 | — | — | US | disclosed |
| US-20100120858-A1 | Piperidine Derivatives | PFIZER INC. | 2010-05-13 | — | — | US | disclosed |
| WO-2009148291-A2 | 3- OR 4-SUBSTITUTED PIPERIDINE COMPOUNDS | SK HOLDINGS CO., LTD. (KR) | 2009-12-10 | — | — | WO | disclosed |
| EP-2066630-A1 | PIPERIDINE DERIVATIVES | Pfizer Products Incorporated (US) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008023258-A1 | PIPERIDINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122927-A1 | 3 OR 4-SUBSTITUTED PIPERIDINE COMPOUNDS | OPRD1, OPRK1, OPRM1 | HPGD 403/4885ITGB3 2309/4885ITGA2B 3346/4885 |
| US-20100120858-A1 | Piperidine Derivatives | P2RX5, P2RX7, P2RX1 | HPGD 2999/4885ITGB3 2077/4885ITGA2B 963/4885 |
| US-20140275072-A1 | MORPHOLINYLBENZOTRIAZINES FOR USE IN CANCER THERAPY | TTBK1, TTBK2, SRMS | HPGD 2726/4885ITGB3 1345/4885ITGA2B 2228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.